ramipril
CLINICAL USE
Angiotensin-converting enzyme inhibitor:Hypertension Secondary prevention of myocardial infarction (MI), stroke or cardiovascular deathHeart failure
DOSE IN NORMAL RENAL FUNCTION
1.25–10 mg once a dayProphylaxis after a MI: 2.5–5 mg twice daily
PHARMACOKINETICS
Molecular weight                           :416.5 %Protein binding                           :56 (as ramiprilat) %Excreted unchanged in urine     : <2 Volume of distribution (L/kg)       :1.2half-life – normal/ESRD (hrs)      :13–17/Increased (as ramiprilat) DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Initial dose 1.25 mg daily and increase according to response <10           : Initial dose 1.25 mg daily and increase according to response DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in GFR <10 mL/min HD                     :Not dialysed. Dose as in GFR <10 mL/min HDF/high flux   :Dialysed. Dose as in GFR <10 mL/min CAV/VVHD      :Dialysed. Dose as in GFR 10 to 20 mL/min IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDsCiclosporin: increased risk of hyperkalaemia and nephrotoxicity Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics Epoetin: increased risk of hyperkalaemia; antagonism of hypotensive effect Lithium: reduced excretion (possibility of enhanced lithium toxicity) Potassium salts: increased risk of hyperkalaemia Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
Metabolised to active metabolite, ramiprilatRenal failure has been reported in association with ACE inhibitors in patients with renal artery stenosis, post renal transplant, and those with congestive heart failureA high incidence of anaphylactoid reactions has been reported in patients dialysed with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor – this combination should therefore be avoidedHyperkalaemia and other side effects more common in patients with impaired renal functionClose monitoring of renal function during therapy is necessary in those patients with known renal insufficiencyNormal doses have been used in CKD 5 .
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home